• On-Demand
  • ABOM Exam Preparation
Review Course for the 2024 ABOM Exam
  • Recorded Webinar
  • On-Demand
  • Pharmacotherapy
Join us for an informative session designed to enhance your expertise in prescribing GLP1 medications for the treatment of obesity.
  • 0.50 AMA PRA Category 1 Credit
  • Recorded Webinar
  • On-Demand
  • Free Obesity Medicine Education (Non-CME)
The 2024 Obesity Medicine Association (OMA) Annual Business Meeting hosted by Lydia Alexander, MD, MFOMA, President of the OMA. 
  • Non-CME
  • Free Obesity Medicine Education (Non-CME)
  • Special Populations
  • Treatment Strategies
Women are particularly affected by weight gain during the menopausal transition, with over 40% of menopausal women estimated to have obesity. During this session, Dr.
  • Non-CME
  • Free Obesity Medicine Education (Non-CME)
  • Nutrition Therapy
Join Dr. Jaime Almandoz and Dr. Colleen Tewksbury for a deep dive into counseling patients regarding nutrition surrounding the use of anti-obesity medications (AOMs).
  • On-Demand
  • ABOM Exam Preparation
Coming Soon: The latest 2025 edition of the SAP will be launched in early 2025. 
  • 9.00 AMA PRA Category 1 Credit
  • On-Demand
  • ABOM Exam Preparation
Coming Soon: The latest 2025 edition of the Pediatric SAP will be launched in early 2025. 
  • 2.00 AMA PRA Category 1 Credit
  • Recorded Webinar
  • On-Demand
  • Adiposity Related Diseases
This session will provide a practical guide to understanding and interpreting continuous glucose monitoring (CGM) data for healthcare providers managing patients with diabetes and obesity.
  • 1.00 AMA PRA Category 1 Credit
  • Conference Recording
  • On-Demand
  • Early Career Learning Pathway
  • Pharmacotherapy
Selecting the correct on label or off label medication to treat obesity can be confusing. The acronym RXAOM provides a framework for individualizing the selection process.
  • 1.00 AMA PRA Category 1 Credit
  • Recorded Webinar
  • On-Demand
  • Early Career Learning Pathway
  • Pharmacotherapy
As the choices available for anti-obesity pharmacotherapy increase, clinicians are faced with options for addressing key clinical scenarios.
  • 1.00 AMA PRA Category 1 Credit

Pages